Tabelecleucel is named as an intervention in 2 current clinical trials in our UK and USA registers. 1 is recruiting patients now. The most common phase is Phase 3. The lead sponsor is Pierre Fabre Medicament. The most-studied condition is Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT03394365 · ClinicalTrials.gov ↗ · Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders
|
Phase 3 | Recruiting | Pierre Fabre Medicament | UK, USA |
|
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
NCT04554914 · ClinicalTrials.gov ↗ · Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)
|
Phase 2 | Active, closed | Pierre Fabre Medicament | UK, USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Pierre Fabre Medicament | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 2 | 1 |
| Clinical trials in USA | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our UK and USA registers name Tabelecleucel as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in UK and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Pierre Fabre Medicament. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tabelecleucel works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tabelecleucel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tabelecleucel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.